Compare ADMA Biologics Inc (ADMA) vs United Parcel Service Inc (UPS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs United Parcel Service Inc — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while United Parcel Service Inc trades at $109.65 (market cap $95.17B). The key difference: United Parcel Service Inc is far larger — about 44.7× ADMA Biologics Inc's market cap, and United Parcel Service Inc pays a 5.86% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | UPS | |
|---|---|---|
Market Cap | $2.13B | $95.17B |
Sector | Health | Industrials |
52-Week High | $20.38 | $120.00 |
52-Week Low | $7.60 | $82.58 |
Enterprise Value | $2.20B | $118.03B |
Volume | — | 2,288,643 |
Dividend Yield | — | 5.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
UPS trades at $111.96, up 1.15% with a bullish technical signal. Recent earnings beat expectations (Q1 2026 EPS of $1.07 vs. $1.02 expected), though revenue declined to $88.66B in 2025. The company invests in healthcare logistics and AI to boost efficiency. Valuation ratios appear reasonable with P/E of 17.8 and P/S of 1.06. Analyst consensus is mixed with 42% buy ratings and a $111 price target.
Outlook: UPS faces revenue pressure but maintains solid profitability (ROE 33.41%). Strategic investments in temperature-controlled facilities and AI could drive growth. Risks include competitive threats and economic sensitivity. The stock offers stability with dividend income, but upside may be limited near the consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
